Management of Parkinson's disease dysarthria: Can artificial intelligence provide the solution?
Speech disorder is a significant problem for people affected with Parkinson's disease (PD) leading to a substantial disability to communicate with others. PD affects the voice, including changes in pitch, intensity, articulation, and syllable rate.We aimed to study the current status of artific...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2022-01-01
|
| Series: | Annals of Indian Academy of Neurology |
| Subjects: | |
| Online Access: | http://www.annalsofian.org/article.asp?issn=0972-2327;year=2022;volume=25;issue=5;spage=810;epage=816;aulast=Kumar |
| Summary: | Speech disorder is a significant problem for people affected with Parkinson's disease (PD) leading to a substantial disability to communicate with others. PD affects the voice, including changes in pitch, intensity, articulation, and syllable rate.We aimed to study the current status of artificial intelligence (AI) using machine learning algorithms (MLAs) in the assessment of speech abnormalities in PD along with the generation of intelligible synthetic speech for voice rehabilitation. We searched the literature for studies focusing on speech/voice disorder in PD and rehabilitation techniques till June 18, 2022. We searched PubMed and Engineering Village (Compendex and Inspec combined) databases. After careful screening of the title and evaluation of abstracts, we used select articles describing the use of AI or its various forms in the management of speech abnormalities in PD to synthesize this review. MLAs classify PD and non-PD patients with an accuracy of more than 90% using only voice features. Non-acoustic sensors can rehabilitate PD patient by converting dysarthric speech to highly intelligible speech using MLAs. MLAs can automatically assess several speech features and quantify the progression of speech abnormalities in PD. PD speech rehabilitation using MLAs may prove superior to other available therapies. |
|---|---|
| ISSN: | 0972-2327 1998-3549 |